Controlling Oncolytic Adenoviruses for Cervical Cancer Treatment
Author Information
Author(s): Anna Kanerva, Sergio Lavilla-Alonso, Mari Raki, Lotta Kangasniemi, Gerd J. Bauerschmitz, Koichi Takayama, Ari Ristimäki, Renee A. Desmond, Akseli Hemminki
Primary Institution: University of Helsinki
Hypothesis
Can anti-inflammatory agents regulate the replication of oncolytic adenoviruses in cervical cancer treatment?
Conclusion
Anti-inflammatory drugs may reduce the replication of adenoviruses, which could be important for managing side effects during treatment.
Supporting Evidence
- Clinical trials have confirmed the safety of selectively oncolytic adenoviruses for treatment of advanced cancers.
- Both Cox-2 and VEGF promoters could be downregulated with anti-inflammatory agents.
- Oncolytic efficacy correlated with promoter activity and in vitro virus production could be abrogated with the substances.
- Dexamethasone reduced the replication of analyzed viruses in vitro.
Takeaway
This study looks at how certain medicines can help control cancer-fighting viruses, making them safer for patients.
Methodology
The study evaluated the effects of anti-inflammatory agents on adenovirus infectivity and oncolytic potency in vitro and in vivo.
Limitations
The inhibitory effect of dexamethasone was not strong enough to provide significant differences in a complex in vivo environment.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website